Original paper

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

Volume: 127, Issue: 10, Pages: 1331 - 1344
Published: Oct 1, 2020
Abstract
PurposeTo compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naïve patients with neovascular age-related macular degeneration (AMD).DesignTwo randomized, multicenter, double-masked, parallel-group, active-controlled, phase 3 clinical trials (CEDAR, SEQUOIA) with identical protocols were conducted. Data from both trials were pooled for...
Paper Details
Title
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
Published Date
Oct 1, 2020
Volume
127
Issue
10
Pages
1331 - 1344
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.